Sign in Subscribe
Biotechnology industries

Advanced Viral Research Corp. Secures Patent in China for AVR118

Strategic Insights

— 1 min read

Advanced Viral Research Corp. (ADVR) has successfully secured patent #ZL 00811493.5 in China for its flagship product AVR118, a biopolymer with novel immunomodulatory activity. This patent, titled "Preparation of a Therapeutic Composition," complements ADVR's existing intellectual property estate and provides additional protection for AVR118. The company's CEO, Elma S. Hawkins, emphasizes the significance of developing a strong international patent portfolio in the biotechnology sector. Concurrently, ADVR is conducting a phase II clinical trial in the United States to evaluate the efficacy of AVR118 in patients with advanced cancers.

Key Takeaways:

  • ADVR has been granted patent #ZL 00811493.5 in China for AVR118, a biopolymer with novel immunomodulatory activity.
  • The patent describes the composition of AVR118 and methods of manufacturing it, providing additional protection for the company's flagship product.
  • AVR118 has demonstrated a favorable safety profile and stimulates proinflammatory responses to combat viral infections and dampen aberrant autoimmune-type inflammatory responses.
  • The phase I/II clinical trial of AVR118 in AIDS patients conducted in Israel showed promising results, including weight gain, mood improvement, and increased ability to perform everyday tasks.
  • ADVR is currently conducting a phase II, multicenter, randomized, double-blind study in the United States to evaluate the effect of a 4.0 ml dose of AVR118 in patients with systemic symptoms related to advanced cancers.
  • Elma S. Hawkins, president and CEO of ADVR, emphasizes the importance of developing a strong worldwide intellectual property estate in the biotechnology sector.

Statistics:

  • 4.0 ml: The dose of AVR118 being evaluated in the ongoing phase II, multicenter, randomized, double-blind study in the United States
  • 2: The number of patents granted by the patent office in China for AVR118
  • 2005: The year in which this article was prepared by Health & Medicine Week editors
  • 30: The number of patients participating in the phase I/II clinical trial of AVR118 in AIDS patients conducted in Israel

Sources:

  • Health & Medicine Week
  • NewsRx.com
  • Advanced Viral Research Corp. (ADVR) press release

Read more